Source: Annual Congress 2006 - COPD – therapy/exacerbations
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. W. Dal Negro, S. Iannazzo, L. Pradelli, M. Eandi (Bussolengo, Torino, Italy). The therapeutic strategies in severe and very severe COPD: a cost-efficacy analysis in Italy. Eur Respir J 2006; 28: Suppl. 50, 293

Member's Comments

No comment yet.

Related content which might interest you: Need for generalized criteria in evaluating the impact of new drugs in clinical trials involving patients suffering from COPD Source: Annual Congress 2006 - Outcomes for COPD pharmacological trials: from lung function to biomarkers Year: 2006 Efficacy of a new standardised approach in reducing severe exacerbations in end stage COPD Source: Eur Respir J 2003; 22: Suppl. 45, 575s Year: 2003 A digital therapy for proactively managing exacerbations and delivering therapeutic benefit to patients with moderate to severe asthma Source: International Congress 2019 – Clinical approach to asthma management Year: 2019 Methodological issues in therapeutic trials of COPD Source: Eur Respir J 2008; 31: 927-933 Year: 2008 Cost-effectiveness analysis of a Home-based disease management intervention for patients with severe COPD alongside the COMET study. Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018 Clinical and functional effectiveness of roflumilast in severe COPD patients Source: Annual Congress 2013 –Modern approach to various clinical settings Year: 2013 The 1-year cost-effectiveness of roflumilast for the treatment of severe to very severe COPD patients Source: Eur Respir J 2007; 30: Suppl. 51, 194s Year: 2007 Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study Source: Eur Respir J 2010; 35: 532-539 Year: 2010 The effectiveness of anti-inflammatory therapy for chronic obstructive pulmonary disease complicated by ischemic heart disease (new medication - new opportunities) Source: International Congress 2014 – Comorbidities Year: 2014 Cost-utility analysis of a Home-based disease management intervention for patients with severe COPD in the COMET study. Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs Year: 2018 Top-10 comorbidities of symptomatic patients with moderate COPD in the clinical setting of the CRYSTAL study Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016 The healthcare burden of non-compliance to pharmacotherapeutic escalation recommendations for COPD Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Can we use a biomarker to guide antibiotic treatment in severe COPD exacerbations? Source: Breathe, 15 (4) 353; 10.1183/20734735.0257-2019 Year: 2019 Optimizing chronic obstructive pulmonary disease (COPD) diagnosis and management to reduce healthcare costs: Systematic review and modeling Source: Annual Congress 2013 –Health economics of airway diseases Year: 2013 Methods for therapeutic trials in COPD: lessons from the TORCH trial Source: Eur Respir J 2009; 34: 1018-1023 Year: 2009 Benefits of triple therapy in moderate, severe, and very severe COPD: subgroup analysis of the ETHOS trial Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 Cost implications for the introduction of omalizumab in to the management of severe chronic asthma in children Source: Eur Respir J 2006; 28: Suppl. 50, 481s Year: 2006 Erdosteine is effective as a treatment for acute exacerbation of COPD: a systematic review of clinical trials Source: International Congress 2017 – COPD management Year: 2017 A self-treatment programme in patients with COPD: Effectiveness for the reduction of severe exacerbations Source: International Congress 2015 – Latest insights into chronic care Year: 2015